Treatment
Bloom syndrome has no specific treatment; however, avoiding sun exposure and using sunscreens can help prevent some of the cutaneous changes associated with photo-sensitivity. Efforts to minimize exposure to other known environmental mutagens are also advisable. Epidemiology
Bloom syndrome is an extremely rare disorder in most populations and the frequency of the disease has not been measured in most populations. However, the disorder is relatively more common amongst people of Central and Eastern European Ashkenazi Jewish background. Approximately 1 in 48,000 Ashkenazi Jews are affected by Bloom syndrome, who account for about one-third of affected individuals worldwide. Blooms Syndrome Registry
The Blooms Syndrome Registry lists 265 individuals reported to have this rare disorder (as of 2009), collected from the time it was first recognized in 1954. The registry was developed as a surveillance mechanism to observe the effects of cancer in the patients, which has shown 122 individuals have been diagnosed with cancer. It also acts as a report to show current findings and data on all aspects of the disorder. See also
Accelerated aging disease
Bloom syndrome (gene)
DNA repair
Progeria
Tumor M2-PK

References
Flanagan M, Cunniff CM (February 14, 2019) [March 22, 2006]. Adam MP, Ardinger HH, Pagon RA,  et al. (eds.). "Bloom syndrome". GeneReviews. Seattle (WA): University of Washington. PMID 20301572. Retrieved July 14, 2019. Further reading
Adam, M. P.; Mirzaa, G. M.; Pagon, R. A.; Wallace, S. E.; Bean LJH; Gripp, K. W.; Amemiya, A. (1993). Margaret P Adam; Holly H Ardinger; Roberta A Pagon; Stephanie E Wallace;  et al. (eds.). GeneReviews. Seattle (WA): University of Washington. ISSN 2372-0697.
Carnosinemia is a rare autosomal recessive metabolic disorder caused by a deficiency of carnosinase, a dipeptidase (a type of enzyme that splits dipeptides into their two amino acid constituents).Carnosine is a dipeptide composed of beta-alanine and histidine, and is found in skeletal muscle and cells of the nervous system. This disorder results in an excess of carnosine in the urine, cerebrospinal fluid, blood, and nervous tissue. Neurological disorders associated with a deficiency of carnosinase, and the resulting carnosinemia ("carnosine in the blood") are common. Symptoms and signs
A variety of neurological symptoms have been associated with carnosinemia. They include: hypotonia, developmental delay, intellectual disability, degeneration of axons, sensory neuropathy, tremors, demyelinization, gray matter anomalies, myoclonic seizures, and loss of purkinje fibers. Genetics
The gene for carnosinase is located on chromosome 18, an autosome. The carnosine dipeptidase-1 gene (CNDP1) controls tissue and serum carnosinase. Mutations in CNDP1 are  responsible for carnosinase deficiency, resulting in carnosinemia.Carnosinemia is an autosomal recessive disorder, which means the defective gene is located on an autosome, and two copies of the defective gene - one from each parent - are required to inherit the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder. Diagnosis
Types
Carnosinase in humans has two forms:1. Cellular, or tissue carnosinase: This form of the enzyme is found in every bodily tissue.